About Prime Medicine Inc
- Industry: Biotechnology
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://primemedicine.com/
Frequently Asked Questions
What is the 52-week range for PRME?
The 52-week high is $6.94 and the 52-week low is $2.67.
What is the P/E ratio for PRME?
The P/E ratio data is currently unavailable.
What is the dividend yield for PRME?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -188.27%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is -4613.11%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 5.18.
Analyst Recommendation Trends
Wall Street analyst consensus for PRME over the last few months:
Latest PRME News
Temporary Weakness in Intellia Stock Seems Like a Buying Opportunity
Here's how to play leading gene-editing stocks as Anthropic's AI tools make progress in the gene-editing space.
Beam Therapeutics: Ignore The Anthropic Noise And Focus On Clinical Progress
Beam Therapeutics (BEAM) stock analysis: BEAM-302 gene-editing upside for 2028â2029, cash runway/dilution risks, valuation vs peersâread now.
Prime: A Buy Due To BLA Filing H1 '27 And Continued PM647 Advancement
Prime Medicine, Inc. maintains a Buy rating, supported by an advancing prime editing pipeline and multiple upcoming clinical catalysts. Click for a PRME update.
Prime Medicine Gets FDA Green Light for Gene Editing Study
The FDA clears Prime Medicine’s IND application for PM647, an investigational in vivo Prime Editor for AATD, for human trials.
Why INLIF Shares Are Trading Higher By Around 78%; Here Are 20 Stocks Moving Premarket
INLIF shares jumped 78% after H1 FY26 revenue rose 26%, gross profit surged 159% and net income turned positive; other premarket movers varied.
Costco Wholesale, Scholastic and 3 Stocks to Watch Heading Into Friday
Scholastic fell on weak results, Costco beat estimates, Prime Medicine gained on FDA clearance, and INLIF surged on revenue growth.
Prime Medicine stock surges on FDA IND clearance
Investing.com -- Prime Medicine Inc (NASDAQ:PRME) shares gained over 12% in after-hours trading Thursday following the FDA's clearance of the company's Investigational New Drug application for PM647, an in vivo gene editing therapy for Alpha-1 Antitrypsin Deficiency.
Prime Medicine Announces U.S. FDA Clearance of Investigational New Drug Application for PM647 in Alpha-1 Antitrypsin Deficiency
-- Clearance highlights continued execution, modularity and momentum across Prime Medicine’s liver franchise, building on recent regulatory clearances for PM577a -- -- Initial clinical data expected in 2027 -- CAMBRIDGE, Mass., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Comp
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers Prime Medicine (NASDAQ:PRME) shares increased by 13.0% to $3.47 during Thursday's after-market session. The market value of their outstanding shares is at $567.7 million. Onconetix (NASDAQ:ONCO) stock rose
FDA Clears Prime Medicine’s IND Application For PM647, Investigational In Vivo Prime Editor For Alpha-1 Antitrypsin Deficiency
-- Clearance highlights continued execution, modularity and momentum across Prime Medicine’s liver franchise, building on recent regulatory clearances for PM577a ---- Initial clinical data expected in 2027 --CAMBRIDGE,
Anthropic AI Discovery Gene-Editing Stocks Falling
Anthropic says Claude identified a novel enzyme system with characteristics reminiscent of CRISPR
CRSP, NTLA, BEAM, PRME, EDIT Shares Slip — Did Claude Just Spook Gene-Editing Stocks?
CRSP shares closed down 6% on Wednesday, while PRME and EDIT stocks declined 12% and 8%, respectively.
10 Health Care Stocks Whale Activity In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner. Traders often
In Vivo Gene Editing Market Size, Share & Trends Analysis - Global Opportunity Analysis & Industry Forecast (2026-2036)
The global in vivo gene editing market was valued at USD 3.4 billion in 2025 and is forecast to reach USD 22.6 billion by 2036, growing at a 16.8% CAGR from 2026. Growth is driven by CRISPR, base and prime editing, LNP and AAV delivery systems, precision medicine investment, and expanding clinical pipelines for genetic disorders, oncology, cardiovascular and neurological diseases. North America leads the market, while Asia-Pacific is expected to grow fastest. Key players include CRISPR Therapeut
Gene-Editing Powerhouse And Its Rivals Surge Toward A Breakout
Crispr stock, alongside other gene-editing equities, pulled a bullish move Thursday — bounding for a breakout from a cup-with-handle base.
Prime Medicine, Inc. (PRME) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Prime Medicine, Inc. (PRME) Morgan Stanley 24th Annual Global Healthcare Conference September 16, 2026 10:00 AM EDTCompany ParticipantsAllan Reine - CEO...
Prime Medicine to Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that company management will participate in three upcoming conferences: Wells Fargo 21st Annual Healthcare Conference: Company management will host 1x1 meetings on Thursday, September 10, 2026, in Boston, MA.H.C. Wainwright 28th Annual Global Investment Conference: Fireside chat
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-06-05 | Chung Wendy | +75,000 | - | - |
| 2026-06-05 | Cahill Thomas | +75,000 | - | - |
| 2026-06-05 | Kelly Michael Aaron | +75,000 | - | - |
| 2026-06-05 | Marrazzo Jeffrey D | +75,000 | - | - |
| 2026-06-05 | Schenkein David P | +75,000 | - | - |
| 2026-06-05 | Foster-Cheek Kaye I | +75,000 | - | - |
| 2026-06-05 | NELSEN ROBERT | +75,000 | - | - |
| 2026-04-16 | Makhni Svetlana Ni | +800,000 | - | - |
| 2026-02-26 | Reine Allan | +1,300,000 | - | - |
| 2026-02-23 | LEE ANN L. | +375,000 | - | - |
| 2026-02-23 | Alenson Carman | +140,000 | - | - |